Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$118.69 USD

118.69
529,903

+0.19 (0.16%)

Updated Sep 4, 2024 12:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: Coronavirus Vaccine Updates From PFE, AZN & JNJ

by Kinjel Shah

WHO authorizes emergency use of AstraZeneca's (AZN) COVID-19 vaccine. J&J (JNJ) seeks conditional approval for its COVID-19 vaccine in EU.

What's in the Cards for Intellia (NTLA) This Earnings Season?

by Zacks Equity Research

Intellia Therapeutics (NTLA) is likely to discuss the progress of its pipeline candidate on its fourth-quarter earnings call.

The Zacks Analyst Blog Highlights: AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline and Novartis

by Zacks Equity Research

The Zacks Analyst Blog Highlights: AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline and Novartis

Alnylam's (ALNY) Q4 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Alnylam (ALNY) reported a wider-than-expected loss but revenues beat estimates in the fourth quarter of 2020.

Kinjel Shah headshot

Pharma Stock Roundup: AZN's Q4 Earnings, FDA Approval for LLY & SNY's Drugs

by Kinjel Shah

AstraZeneca (AZN) announces Q4 results. FDA approves Lilly's COVID-19 antibody cocktail & Sanofi's (SNY) Libtayo for a new indication.

Novartis (NVS) Gets Breakthrough Therapy Tag for Leukemia Drug

by Zacks Equity Research

Novartis' (NVS) asciminib gets Breakthrough Therapy tag by the FDA for the treatment of adult patients with Ph+ CML in chronic phase, previously treated with two or more tyrosine kinase inhibitors.

Bristol Myers (BMY) Gets FDA Approval for CAR T-Cell Therapy

by Zacks Equity Research

Bristol Myers (BMY) obtains FDA approval of CAR T cell therapy, Breyanzi, for the treatment of lymphoma.

Roche (RHHBY) 2020 Earnings Down Due to Biosimilars, COVID-19

by Zacks Equity Research

Roche's (RHHBY) performance in 2020 gets negatively impacted by biosimilar competition and coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.

Regeneron (REGN) Q4 Earnings, Sales Beat on Solid Dupixent Show

by Zacks Equity Research

Regeneron (REGN) beats on Q4 earnings and sales on solid performance of Dupixent, Eylea and incremental contribution from oncology drug, Libtayo.

Incyte (INCY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports fourth-quarter 2020 results.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q4 Earnings, MRK & LLY's Coronavirus Updates

by Kinjel Shah

J&J (JNJ) and Novartis (NVS) announce Q4 results. Merck (MRK), AbbVie (ABBV) & Pfizer (PFE) get EU approvals.

Will Glaxo (GSK) Q4 Earnings Recover From Coronavirus Woes?

by Zacks Equity Research

Glaxo's (GSK) new and specialty products are likely to have driven fourth-quarter sales. The results will provide clarity on the impact of coronavirus on the company's vaccine business.

Novartis (NVS) Misses on Q4 Earnings, Issues Grim 2021 Outlook

by Zacks Equity Research

Novartis (NVS) reports dismal fourth-quarter results as the pandemic affected sales. The outlook for 2021 also indicates challenges ahead.

Incyte's (INCY) BLA for Cancer Drug Accepted for Priority Review

by Zacks Equity Research

Incyte's (INCY) application for pipeline candidate, retifanlimab, for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) gets Priority Review.

Regional Banks Post Mixed Earnings Results

by Zacks Equity Research

Regional Banks Post Mixed Earnings Results.

Mark Vickery headshot

Q4 Earnings Come to Regional Banks: ALLY, HBAN & More

by Mark Vickery

Most of the Big Banks have already posted for Q4; this morning we see a large share of Regional Banks reporting quarterly earnings.

Merck's (MRK) Heart Failure Drug Vericiguat Gets FDA Nod

by Zacks Equity Research

Merck (MRK)/Bayer's (BAYRY) vericiguat gets FDA approval for symptomatic chronic heart failure and reduced ejection fraction

Roche's (RHHBY) Esbriet sNDA Gets Priority Review From FDA

by Zacks Equity Research

The FDA accepts Roche's (RHHBY) sNDA for Esbriet under a priority review to treat unclassifiable interstitial lung disease. A verdict from the regulatory body is awaited in May 2021.

The Zacks Analyst Blog Highlights: Novartis, QUALCOMM, Accenture, MetLife and Electronic Arts

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Novartis, QUALCOMM, Accenture, MetLife and Electronic Arts

Sheraz Mian headshot

Top Stock Reports for Novartis, QUALCOMM & Accenture

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), QUALCOMM (QCOM), and Accenture (ACN).

BeiGene (BGNE) Up on Label Expansion of Tislelizumab in China

by Zacks Equity Research

BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.

Novartis' (NVS) Ligelizumab Gets Breakthrough Therapy Status

by Zacks Equity Research

Novartis (NVS) gets Breakthrough Therapy designation by the FDA for ligelizumab for the treatment of chronic spontaneous urticaria.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's Alzheimer Disease Data, NVS & SNY's M&A Deals

by Kinjel Shah

Lilly's (LLY) candidate, donanemab shows slowing of cognitive decline in Alzheimer's disease patients. Novartis (NVS) and Sanofi (SNY) announce M&A deals.

Alexion (ALXN) to Pause Enrollment in COVID-19 Study on Ultomiris

by Zacks Equity Research

Alexion (ALXN) decides to stop further enrollment in the late-stage study of Ultomiris in adults with severe COVID-19 requiring mechanical ventilation due to lack of efficacy.

Novartis (NVS) In-Licenses Anti-PD-1 Antibody from BeiGene

by Zacks Equity Research

Novartis (NVS) in-licenses BeiGene's anti-PD-1 monoclonal antibody, tislelizumab, in major markets outside of China.